Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mahadi Ali Baig"'
Publikováno v:
Opuholi Golovy i Šei, Vol 8, Iss 3, Pp 53-60 (2018)
We present an updated analysis of lenvatinib in radioiodine-refractory differentiated thyroid cancer (RR-DTC) with new duration of response (DOR) data unavailable for the primary analysis. In this randomized, double-blind, multicenter, placebo-contro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a3ba1578abc7de57b5aba8887762bab
https://ogsh.abvpress.ru/jour/article/view/361
https://ogsh.abvpress.ru/jour/article/view/361
Publikováno v:
Endocrine-Related Cancer
We present an updated analysis of lenvatinib in radioiodine-refractory differentiated thyroid cancer (RR-DTC) with new duration of response (DOR) data unavailable for the primary analysis. In this randomized, double-blind, multicenter, placebo-contro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23d30a5cdb9dada6b8146ce94adacedc
http://europepmc.org/articles/PMC5958278
http://europepmc.org/articles/PMC5958278
Autor:
Mahadi Ali Baig, Gary Richardson, Caimiao Wei, Keiichi Fujiwara, Bradley J. Monk, Michael J. Birrer, Ramez N. Eskander, Stephanie Gaillard, Jonathan A. Ledermann, Fabian Zohren
Publikováno v:
Journal of Clinical Oncology. 37:TPS9-TPS9
TPS9 Background: Preclinical studies suggest that chemotherapy (CTX) and PARP inhibitors may increase tumor antigenicity, providing a rationale for combined treatment with checkpoint inhibitors in patients (pts) with ovarian cancer (OC). Talazoparib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b39b85ea5d89287d1062ac81834ca3f6
https://doi.org/10.1200/jco.2019.37.8_suppl.tps9
https://doi.org/10.1200/jco.2019.37.8_suppl.tps9
Autor:
Corina E. Dutcus, Mahadi Ali Baig, Masatoshi Eto, Di Li, Thomas E. Hutson, Robert J. Motzer, Viktor Grünwald, Toni K. Choueiri, Lea Dutta, Camillo Porta, Thomas Powles
Publikováno v:
Journal of Clinical Oncology. 36:TPS706-TPS706
TPS706 Background: Lenvatinib (LEN) is a multikinase inhibitor of vascular endothelial growth factor (VEGF) receptor 1–3, fibroblast growth factor receptor 1–4, platelet-derived growth factor receptor alpha, and RET and KIT. Based on a phase 2 st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0dc5f46f97f0038907ad90e8da84b224
https://doi.org/10.1200/jco.2018.36.6_suppl.tps706
https://doi.org/10.1200/jco.2018.36.6_suppl.tps706
Autor:
Robert J. Motzer, Viktor Grünwald, Thomas E. Hutson, Camillo Porta, Thomas Powles, Masatoshi Eto, Corina E Dutcus, Mahadi Ali Baig, Lea Dutta, Di Li, Toni K. Choueiri
Publikováno v:
Journal of Clinical Oncology. 35:TPS4595-TPS4595
TPS4595 Background: Lenvatinib (LEN) is a multikinase inhibitor of vascular endothelial growth factor (VEGF) receptor 1–3, fibroblast growth factor receptor 1–4, platelet-derived growth factor receptor alpha, and RET and KIT. Based on a phase 2 s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8467fdf4f15eb07f3d1bed77a083a604
https://doi.org/10.1200/jco.2017.35.15_suppl.tps4595
https://doi.org/10.1200/jco.2017.35.15_suppl.tps4595
Publikováno v:
Journal of Clinical Oncology. 34:4553-4553
4553Background: In the randomized phase 2 study of LEN, EVE, and LEN+EVE in mRCC, LEN+EVE significantly improved the primary endpoint median progression-free survival (PFS) vs EVE (14.6 vs 5.5 mont...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c4780d391f42a429a8bbd32ab17bf38
https://doi.org/10.1200/jco.2016.34.15_suppl.4553
https://doi.org/10.1200/jco.2016.34.15_suppl.4553